Pipeline

The broad and balanced late-stage product portfolio includes novel treatments for resistant bacterial infections, systemic fungal infections, and severe skin diseases.

 

The company's diversified portfolio includes two commercialized drugs (alitretinoin, ceftobiprole), one investigational drug (isavuconazole) in phase III as well as substantial innovative early-stage programs. Alitretinoin belongs to the well studied family of retinoids and is targeted at patients with severe chronic hand eczema who do not respond to topical corticosteroids. Toctino® (alitretinoin) is marketed in Denmark, France, Germany, Switzerland and the United Kingdom. It is approved in six additional European countries as well as in Canada and has been recommended for approval in 15 European countries. Ceftobiprole, an anti-MRSA broad-spectrum cephalosporin antibiotic is marketed in Canada under the trade name ZEFTERA™. Ceftobiprole is approved in Switzerland under the trade name Zevtera™ for the treatment of complicated skin and soft tissue infections including diabetic foot infections. Isavuconazole is a novel broad-spectrum antifungal for the treatment of severe invasive fungal infections. Basilea has entered into a license, co-development and co-promotion agreement with Astellas Pharma Inc. for isavuconazole for the treatment of life-threatening invasive fungal infections on a worldwide basis, including an option for Japan.